Developmental effects of SSRIs: lessons learned from animal studies.
Selective serotonin reuptake inhibitors (SSRIs) are utilized in the treatment of depression in pregnant and lactating women. SSRIs may be passed to the fetus through the placenta and the neonate through breastfeeding, potentially exposing them to SSRIs during peri- and postnatal development. However, the long-term effects of this SSRI exposure are still largely unknown. The simplicity and genetic amenability of model organisms provides a critical experimental advantage compared to studies with humans. This review will assess the current research done in animals that sheds light on the role of serotonin during development and the possible effects of SSRIs. Experimental studies in rodents show that administration of SSRIs during a key developmental window creates changes in brain circuitry and maladaptive behaviors that persist into adulthood. Similar changes result from the inhibition of the serotonin transporter or monoamine oxidase, implicating these two regulators of serotonin signaling in developmental changes. Understanding the role of serotonin in brain development is critical to identifying the possible effects of SSRI exposure.
Borue
Xenia
X
University of Virginia Medical Scientist Training Program and University of Virginia Neuroscience Graduate Program, Charlottesville, VA 22904, USA.
Chen
John
J
Condron
Barry G
BG
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000196:embryology* / Q000503:physiopathology; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008995:Monoamine Oxidase / Q000187:drug effects / Q000378:metabolism; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced* / Q000378:metabolism / Q000503:physiopathology; D012701:Serotonin / Q000378:metabolism / Q000502:physiology*; D050486:Serotonin Plasma Membrane Transport Proteins / Q000187:drug effects / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
D008995:Monoamine Oxidase; D012701:Serotonin; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12730-5
11675504
J Neurosci. 2001 Sep 1;21(17):6862-73
11517274
Physiol Behav. 2002 Mar;75(3):403-10
11897268
Pharmacogenomics J. 2002;2(4):217-35
12196911
J Neurosci. 2002 Oct 1;22(19):8541-52
12351728
Endocrinology. 2002 Dec;143(12):4520-6
12446578
Neuron. 2003 Jan 23;37(2):233-47
12546819
Am J Psychiatry. 2003 May;160(5):993-6
12727706
Brain Res Bull. 2003 May 30;60(4):345-53
12781323
J Neurochem. 2003 Jul;86(1):210-9
12807440
Science. 2003 Jul 18;301(5631):386-9
12869766
Dev Neurosci. 2003 Mar-Aug;25(2-4):245-56
12966221
Behav Pharmacol. 2003 Sep;14(5-6):369-83
14501251
Nat Rev Neurosci. 2003 Dec;4(12):1002-12
14618156
Biol Psychiatry. 2003 Nov 15;54(10):953-9
14625137
Biol Psychiatry. 2003 Nov 15;54(10):960-71
14625138
Neuropsychopharmacology. 2003 Dec;28(12):2077-88
12968128
Genes Brain Behav. 2003 Dec;2(6):365-80
14653308
Development. 2004 Mar;131(5):997-1006
14973268
J Neurosci. 2004 Feb 18;24(7):1652-9
14973240
Mol Interv. 2004 Apr;4(2):109-23
15087484
Brain Res Dev Brain Res. 2004 Jun 21;150(2):151-61
15158078
Am J Psychiatry. 2004 Jun;161(6):1066-78
15169695
Neuroreport. 2004 Sep 15;15(13):2097-101
15486489
Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15506-11
15483108
Science. 2004 Oct 29;306(5697):879-81
15514160
Brain Res. 1981 Jan 5;204(1):129-46
7195762
Proc Natl Acad Sci U S A. 1987 Jun;84(12):4322-6
3473503
EXS. 1993;63:266-78
8422538
J Neurobiol. 1994 Jun;25(6):666-93
8071666
J Comp Neurol. 1994 Oct 8;348(2):277-90
7814692
Neuron. 1995 May;14(5):899-912
7748558
Neuron. 1996 Nov;17(5):823-35
8938116
Curr Biol. 1997 Oct 1;7(10):813-6
9368767
J Pharmacol Exp Ther. 1997 Dec;283(3):1333-41
9400008
Neuron. 1997 Dec;19(6):1285-96
9427251
Mol Pharmacol. 1998 Apr;53(4):649-55
9547354
Eur J Pharmacol. 1998 Jul 10;352(2-3):307-15
9716368
J Neural Transm (Vienna). 1998;105(10-12):1335-9
9928901
J Neurosci. 1999 Aug 15;19(16):7007-24
10436056
Neuropharmacology. 1999 Aug;38(8):1083-152
10462127
Chin J Physiol. 1999 Jun 30;42(2):53-9
10513599
J Neurosci Methods. 2004 Dec 30;140(1-2):169-81
15589347
Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 5;133B(1):110-5
15578606
Int J Dev Neurosci. 2005 Feb;23(1):75-83
15730889
Neuron. 2005 Apr 7;46(1):65-74
15820694
Mol Psychiatry. 2005 Aug;10(8):782-9, 714
15940298
Neuropharmacology. 2005 Nov;49(6):798-810
16183083
Neuropsychopharmacology. 2006 Jan;31(1):47-57
16012532
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6269-74
16569698
J Neurosci. 2006 May 17;26(20):5554-64
16707806
Mol Neurobiol. 2006 Aug;34(1):51-66
17003521
Behav Brain Res. 2007 Jan 10;176(1):94-108
17034875
Cereb Cortex. 2000 Feb;10(2):181-91
10667986
Pediatrics. 2000 Apr;105(4 Pt 1):880-7
10742343
J Neurosci. 2001 Feb 1;21(3):884-96
11157075
Psychopharmacology (Berl). 2001 May;155(3):315-22
11432695
Brain Res Bull. 2001 Nov 15;56(5):487-94
11750794